BLASUBCUTANEOUSINJECTABLE
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
IRA Negotiated
PYZCHIVA (ustekinumab-ttwe) by Samsung Bioepis is interleukin-12 antagonists [moa]. First approved in 2024.
Drug data last refreshed 6h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PYZCHIVA (ustekinumab-ttwe) is a monoclonal antibody antagonist of interleukin-12, approved June 2024 as a biosimilar referencing the original ustekinumab. It is administered subcutaneously for immune-mediated inflammatory conditions where IL-12 inhibition provides therapeutic benefit.
Growth
Early-stage biosimilar in growth phase with significant price pressure from IRA negotiation; commercial teams will focus on payer access and provider education to capture market share from the reference product.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PYZCHIVA represents a biosimilar commercialization opportunity in a competitive IL-12 space with established demand but aggressive pricing pressure. Roles on this team emphasize payer strategy, formulary placement, and provider conversion rather than disease education or clinical development.
Brand ManagerMarket Access Manager
Worked on PYZCHIVA at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.